コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 l chemotherapy (oxaliplatin, 5-Flourouracil, folinic acid).
2 cells was unable to support growth in 15 pM folinic acid.
3 ate than wild-type L1210 cells when grown on folinic acid.
4 m(2) of irinotecan base) or fluorouracil and folinic acid.
5 accumulation of polyglutamylated species of folinic acid.
6 eficiency can be corrected by treatment with folinic acid.
7 175 mg) L-folinic acid or low-dose (25 mg) L-folinic acid.
8 ation of pyrimethamine with sulfadiazine and folinic acid.
9 imum of 12 cycles (oxaliplatin 85 mg/m(2), L-folinic acid 175 mg [or folinic acid 350 mg], fluorourac
10 e cycles of OxMdG [oxaliplatin 85 mg/m(2), l-folinic acid 175 mg, fluorouracil 400 mg/m(2) bolus, the
11 /m(2) administered intravenously over 2 h, l-folinic acid (175 mg flat dose administered intravenousl
12 randomized to receive 12 weeks of high-dose folinic acid (2 mg kg(-1) per day, maximum 50 mg per day
14 py (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6
15 eived either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, f
16 omly assigned the de Gramont regimen (n=303; folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2)
17 r IHA chemotherapy designed to be equitoxic (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 m
18 to receive either intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg2 and 2
19 platin 85 mg/m(2), L-folinic acid 175 mg [or folinic acid 350 mg], fluorouracil 400 mg/m(2) [bolus],
20 administered intravenously over 2 h) or d,l-folinic acid (350 mg flat dose administered intravenousl
21 therapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.
22 ing the de novo folate biosynthesis pathway, folinic acid (5-CHO-THF) could no longer support the fol
23 ecDHFR, EC 1.5.1.3) as a binary complex with folinic acid (5-formyl-5,6,7,8-tetrahydrofolate; also ca
25 ions usually include combination regimens of folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxa
26 a common combination chemotherapy, FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) in a 3D pr
27 the viability of colorectal cancer (CRC) and folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX)-r
28 nts that incorporate the same drug cocktail (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan
29 folate derivative 5-formyltetrahydrofolate (folinic acid; 5-CHO-THF) was discovered over 40 years ag
31 ngly, flavivirus replication was restored by folinic acid, a thymidine precursor, in the presence of
32 utoantibody and treating them with high-dose folinic acid along with other interventions to lower the
34 indicated that FUEL is unable to metabolize folinic acid (also known as leucovorin or 5-formyltetrah
35 for patients treated with fluorouracil plus folinic acid and 23.6 (95% CI, 21.4-26.4) months for tho
38 emcitabine therapy were randomly assigned to folinic acid and fluorouracil (FF) or oxaliplatin and FF
39 f cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered
41 f antidotes (ethanol or fomepizole and folic/folinic acid) and consideration of extracorporeal treatm
43 oocyte(-1)), (2) inhibited by methotrexate, folinic acid, and folic acid (Ki = 0.84 micromol/L, 0.71
45 lorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab un
46 ium containing dialyzed serum and 15 pM [6S]-folinic acid, and parental DC-3F cells were compared by
47 was significantly greater in those receiving folinic acid as compared with those receiving placebo, r
48 nificantly greater in participants receiving folinic acid as compared with those receiving placebo, r
49 ous small molecules (for example, pyridoxal, folinic acid, ATP, and AMP) also convert the solution of
50 targeted nutritional intervention trial with folinic acid, betaine, and methylcobalamin was initiated
52 and this blockade is effectively relieved by folinic acid, but not by folic acid, supplementation.
58 ucturally related compounds (including DOPA, folinic acid, etc.) and 13 other compounds (such as carn
59 2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a
60 notecan in combination with fluorouracil and folinic acid extends survival with a manageable safety p
61 tin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with
63 ity, and effectiveness of the combination of folinic acid (FA)/fluorouracil (5-FU) followed by escala
64 duction or consolidation leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin chemotherap
65 ortive care (BSC) (n = 4), an association of folinic acid, fluorouracil and oxaliplatin (FOLFOX) (n =
66 inic acid], fluorouracil, and oxaliplatin or folinic acid, fluorouracil, and irinotecan hydrochloride
67 the benefit derived from second-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherap
68 atin-based regimens (modified FOLFOX-6 [levo-folinic acid, fluorouracil, and oxaliplatin]/modified CA
69 hemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin).
70 has demonstrated the superiority of modified folinic acid, fluorouracil, irinotecan, and oxaliplatin
71 ated with 3 months of chemotherapy (modified folinic acid-fluorouracil-oxaliplatin 6 or capecitabine-
72 ed doublet chemotherapy (leucovorin calcium [folinic acid], fluorouracil, and oxaliplatin or folinic
74 m)FOLFIRINOX ([modified] leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, a
77 ultiple regimens including NALIRI + 5-FU and folinic acid, FOLFIRINOX, 5-FU-based oxaliplatin doublet
78 Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolu
79 anguage impairment, treatment with high-dose folinic acid for 12 weeks resulted in improvement in ver
80 followed by pyrimethamine, sulfadiazine, and folinic acid for at least 4 weeks in combination with a
81 ration of treatment with both pyridoxine and folinic acid for patients with alpha-AASA dehydrogenase
82 eophylline, hypoxanthine, cyclic-di-GMP, and folinic acid from libraries of ~22,700 sequences in tota
83 to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients with RAS wild-type meta
84 tal cancer (mCRC) receiving fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab)
85 phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by f
86 id, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and
87 Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved ove
88 r Children were significantly greater in the folinic acid group as compared with the placebo group.
89 ion group, 83 (58%) in the fluorouracil plus folinic acid group, and 73 (52%) in the gemcitabine grou
90 n patients (14%) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse ev
91 s 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.0
92 Adjuvant chemotherapy with fluorouracil and folinic acid improves overall survival for resected carc
93 We sought to determine whether high-dose folinic acid improves verbal communication in children w
95 d less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer
96 efficacy tested, together with the non-toxic folinic acid, in preclinical murine models of pancreatic
97 herapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infection stage of the f
99 duced NF-kappaB suppression by thymidine and folinic acid indicates the role of the thymidylate synth
100 n longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX)
101 itive for these autoantibodies and high-dose folinic acid is beneficial in treating these children.
102 associated with the presence in MCDB 402 of folinic acid, known clinically as leucovorin, which is a
103 romising combination chemotherapy regimen of folinic acid (leucovorin), fluorouracil, irinotecan, and
104 cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxa
105 ations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin)
107 tional intervention with methylcobalamin and folinic acid may be of clinical benefit in some children
108 SUCRA score (SUCRA = 0.91), NALIRI + 5-FU + folinic acid may be the optimal choice for improved PFS
109 rding to the NMA results, NALIRI + 5-FU, and folinic acid may represent the best second-line treatmen
111 s treated with single-agent methotrexate and folinic acid (MTX-FA; SIR, 0.7; 95% CI, 0.5 to 1.1) and
112 noliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monothera
114 o receive chemotherapy with fluorouracil and folinic acid (n=1622) or to observation (with chemothera
115 ge positive binding co-operativity) and DHFR.folinic acid.NADPH (large negative binding co-operativit
117 linic acid] than to FOLFOX (5-FU+oxaliplatin+folinic acid), not only between isogenic tumors but also
120 st-line zolbetuximab plus mFOLFOX6 (modified folinic acid [or levofolinate], fluorouracil, and oxalip
122 ab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in
123 Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizum
124 icacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined with
125 dard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of
126 intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gr
127 nous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration.
128 (2) high-dose intravenous methotrexate with folinic acid rescue and continuing intrathecal methotrex
129 alated-dose intravenous methotrexate without folinic acid rescue during interim maintenance courses.
130 mitochondrial encephalopathy (two patients), folinic acid-responsive epilepsy (one patient) and a mov
134 n other anonymous individuals diagnosed with folinic acid-responsive seizures showed similar results.
135 two patients whose CSF showed the marker of folinic acid-responsive seizures, but who responded clin
136 Supplementing pregnant Folbp1+/- dams with folinic acid reversed this phenotype in nullizygous pups
138 Treatments in Poisoning inhibitors and folic/folinic acid should be continued during extracorporeal t
139 1 (folr1) overexpression and treatment with folinic acid, stimulated B-cell differentiation in zebra
142 omized to receive either daily folic acid or folinic acid supplements during an additional week of MT
143 ty to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplatin+folinic a
144 ion symptom inventories after treatment with folinic acid; the patient with low tetrahydrobiopterin a
146 observations, we find that administration of folinic acid to mice bearing PDA increases NKT cells in
147 lowing treatment, we observed penetration of folinic acid to the core of spheroids and metabolism of
148 ith/without B-cell ablation and with/without folinic acid treatment indicated B-cell regeneration cou
149 ffect size (Cohen's d=0.91), indicating that folinic acid treatment may be more efficacious in childr
150 mprovements in ASD symptoms with leucovorin (folinic acid) treatment have been reported in some child
153 s in the QUASAR trial (adjuvant fluorouracil/folinic acid v observation in stage II/III CRC) was anal
154 n group, 143 patients to receive 20 mg/m2 of folinic acid via intravenous bolus injection followed by
155 noliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 mont
156 owed that the combination of NALIRI + 5-FU + folinic acid was most likely to yield the highest OS res
157 noliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15
158 eraction can be modulated by the presence of folinic acid, which induces a local structural change at
159 he metabolic precursors, methylcobalamin and folinic acid, would improve plasma concentrations of tra